CAMX.STライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 18:09):

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally...

Stats
本日の出来高	127 916
平均出来高	110 816
時価総額	29.88B
EPS	SEK0 ( 2024-05-07 )
次の収益日	( SEK0 ) 2024-07-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	69.23
ATR14	SEK1.527 (0.29%)

ボリューム相関

長: 0.35 (neutral)

短: -0.63 (weak negative)

Signal:(42.411) Neutral

Camurus AB (publ) 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Camurus AB (publ) 相関 - 通貨/商品

-0.19
( neutral )

0.00
( neutral )

-0.45
( neutral )

0.47
( neutral )

0.11
( neutral )

0.18
( neutral )

Camurus AB (publ) 財務諸表

Annual	2023
収益:	SEK1.72B
総利益:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2023
収益:	SEK1.72B
総利益:	SEK1.58B (92.06 %)
EPS:	SEK7.78

FY	2022
収益:	SEK956.34M
総利益:	SEK853.08M (89.20 %)
EPS:	SEK1.010

FY	2021
収益:	SEK600.57M
総利益:	SEK515.22M (85.79 %)
EPS:	SEK-1.660

Financial Reports:

No articles found.

Camurus AB (publ)

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.